In July, the U.S. economy suffered from a 32.9% contraction in GDP, the largest in recent history. Despite a partial bounce back in GDP and intensifying pandemic effects, biotech venture funding, IPOs, and biotech stock indexes have reached record highs in 2020. Will investors remain confident in biotechnology companies? Will vaccine roll-out performance affect investment in non-vaccine biotechs or spark a rally in M&A? Are there best practices that company executives and business development professionals should consider for fundraising and deal making? Attend to hear success stories and challenges as economic, political, and public health uncertainty rise even higher than 6 months ago.